Nivolumab/CCRT Followed by Nivolumab/Ipilimumab Misses PFS End Point in Select Stage III NSCLC
CheckMate 73L missed its primary end point of PFS in advanced unresectable stage III non–small cell lung cancer.
Related Articles
Outpatient Lymphodepletion Before Brexu-Cel Remains Safe, Efficacious in Mantle Cell Lymphoma and Acute Lymphoblastic Leukemia
Outpatient lymphodepletion prior to brexu-cel was safe and generated comparable 60-day non-relapse mortality vs inpatient administration in B-ALL and MCL.
Humble Typhoon amid Haughty Tycoons
Frank Tyson (1930 – 2015) Pacers in cricket are a privileged and pampered tribe; their whimsicalities, pet mannerisms, and even tantrums are happily made part…
Pelabresib Plus Ruxolitinib Leads to Sustained Responses in JAK Inhibitor-Naive Myelofibrosis
Improvements in the 4 hallmarks of myelofibrosis were observed with pelabresib plus ruxolitinib vs placebo plus ruxolitinib in JAK inhibitor-naive disease.
Pembrolizumab/Chemo, Followed by Olaparib Maintenance, Boosts PFS in Advanced Ovarian Cancer
Pembrolizumab plus chemotherapy, followed by olaparib with or without bevacizumab, improved PFS in advanced ovarian cancer.
Updates: MSK – Anthem Blue Cross Insurance Contract Negotiations
Stay updated with the latest on the MSK and Anthem Blue Cross insurance negotiations to keep Memorial Sloan Kettering Cancer Center as an in-network provider.
Middle East crisis live: Israel orders closure of one of last functioning hospitals in northern Gaza
Head of Kamal Adwan hospital says it is ‘next to impossible’ to obey shut down order due to lack of ambulances to evacuate patients
Prophylactic Tocilizumab Reduces Toxicity, Boosts Efficacy in Immune Checkpoint Inhibitor–Treated Melanoma
Matthew Hadfield, DO, discusses findings from a phase 2 study that used tocilizumab to reduce toxicities with immune checkpoint inhibitors in melanoma.
How to make transplanted stem cells feel at home
In this issue of Blood, Verkamp and colleagues1 present a retrospective analysis of the emapalumab (anti-interferon gamma [IFN-γ] monoclonal antibody) use
Remote Symptom Monitoring of Patients With Advanced Lung Cancer (The ProWide Study): A Randomized Controlled Trial | JCO Oncology Practice
PURPOSERemote symptom monitoring of patients with cancer has previously shown potential for improving clinical outcomes. This study aimed to evaluate the effects of remote symptom…
Myasthenia Gravis Research Highlights: AAN 2024
Nicholas Silvestri, MD, of the Univ of Buffalo, provides an overview of the latest myasthenia gravis clinical research presented at AAN 2024.
